<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005575</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032069</org_study_id>
    <nct_id>NCT02005575</nct_id>
  </id_info>
  <brief_title>The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade</brief_title>
  <official_title>The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <brief_summary>
    <textblock>
      The proposed study is a randomized, double-blinded, non-placebo-controlled evaluation of the&#xD;
      effect of the addition of dexamethasone to intraoperative intercostal nerve block bupivicaine&#xD;
      solutions on the duration of pain relief and post operative pulmonary function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study proposes two groups of 25 patients undergoing similar VATS surgery with a single&#xD;
      surgeon, Dr. R. McKenna, who will receive interoperatively placed intercostal nerve blocks at&#xD;
      the same levels. Each group will receive intercostals nerve blocks with one of two different&#xD;
      solutions: group one will receive intercostal nerve blocks with only 0.46% bupivacaine (19.5&#xD;
      ml of 0.5% bupivacaine + .5 cc saline), group 2 will receive intercostal blocks with 0.46%&#xD;
      bupivacaine and dexamethasone(19.5 ml of 0.5% bupivacaine + .5ml .4% dexamethasone). The&#xD;
      patients will have pulmonary lung function objectively assessed by portable spirometry and&#xD;
      clinical factors both preoperatively and postoperatively. Our study objective is to examine&#xD;
      and quantify the potentially beneficial effects of intercostal nerve blockade prolongation&#xD;
      with dexamethasone on postoperative pulmonary function and postoperative recovery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post operative pain</measure>
    <time_frame>72 hours post operatively</time_frame>
    <description>Patients will be evaluated for post operative pain using the NRS pain evaulation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Post Minimally Invasive Thorascopic Surgical Pain</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine and Dexamethasone</intervention_name>
    <description>The standard of care is to use a regional block solution containing both decadron and bupivicaine.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 - 80 years old of either gender, scheduled for unilateral VATS procedure with Dr.&#xD;
             McKenna for resection of lung tumor.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA IV and above&#xD;
&#xD;
          -  Intolerance, allergy, or contraindication to use of any medications used in this study&#xD;
&#xD;
          -  Significant coronary artery disease (abnormal stress test, myocardial infarction&#xD;
             within the last 3 months)&#xD;
&#xD;
          -  Uncontrolled hypertension (BP &gt; 140/90)&#xD;
&#xD;
          -  History of prior ipsilateral thorascopic surgery&#xD;
&#xD;
          -  Cardiac arrhythmias particularly prolonged QT syndrome&#xD;
&#xD;
          -  Drugs known to cause prolonged qT: class IA antiarrhythmics (quinidine, procainamide,&#xD;
             dysopyramide), class III antiarrhythmics (sotalol, dofetalide, ibutalide, amiodarone),&#xD;
             haloperidol, thioridazine, arsenic trioxide, HIV protease inhibitors, tricyclic&#xD;
             antidepressants&#xD;
&#xD;
          -  Individuals with significant psychological disorders including: schizophrenia, mania,&#xD;
             bipolar disorder or psychosis&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Morbid obesity (BMI &gt; 40 kg/m2) AND/OR weight &gt; 150 kg&#xD;
&#xD;
          -  Chronic renal failure ( creatinine &gt; 2.0 mg/dL)&#xD;
&#xD;
          -  Liver failure e.g., active cirrhosis&#xD;
&#xD;
          -  Alcohol or substance abuse within in the past 3 months&#xD;
&#xD;
          -  Uncorrected hypokalemia, hypomagnesemia, hypocalcemia (can be due to diuretics,&#xD;
             mineralocorticoid use, laxatives)&#xD;
&#xD;
          -  Restrictive lung disease (pulmonary fibrosis, myasthenia gravis) or FEV1 or FEV less&#xD;
             than 70% of predicted value.&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Neuropathic pain&#xD;
&#xD;
          -  Chronic opioid consumption (&gt;30mg oxycodone or greater per day)&#xD;
&#xD;
          -  Cahexia from any cause&#xD;
&#xD;
          -  systemic use of corticosteroids for greater than 2 weeks in the 6 months prior to&#xD;
             surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>dermot Maher</investigator_full_name>
    <investigator_title>Resident Department of Anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 11, 2015</submitted>
    <returned>May 27, 2015</returned>
    <submitted>July 6, 2017</submitted>
    <returned>July 31, 2017</returned>
    <submitted>September 7, 2017</submitted>
    <returned>March 29, 2018</returned>
    <submitted>July 16, 2019</submitted>
    <returned>August 22, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

